小剂量尿激酶合用尼莫地平治疗急性脑梗死的临床研究

A Clinical Observation of a Combined Therapy of Low-dose of Urokinase and Nimodipine in Treating Acute Cerebral Infarction

目的:探讨小剂量尿激酶合用尼莫地平治疗急性脑梗死患者的疗效。方法:选择发病6-72h的急性脑梗死患者120例,随机分为对照组、尿激酶组和尼莫地平组各40例。全部患者给予常规治疗,尿激酶组还给予尿激酶治疗,尼莫地平组给予尿激酶+尼莫地平,并于治疗前和治疗后14及30d采用NIHSS、BI量表评价患者神经功能。结果:治疗后14及30d尿激酶组、尼莫地平组的NIHSS评分明显优于对照组(P<0.05),且尼莫地平组在治疗后30d明显优于尿激酶组(P<0.05);治疗后14d、30d尿激酶组的BI评分明显优于对照组(P<0.05),尼莫地平组与对照组比较则有显著差异(P<0.01),且明显优于尿激酶组(P<0.05)。结论:小剂量尿激酶合用尼莫地平治疗急性脑梗死可以有效改善急性缺血性脑损害患者的神经功能缺损,提高生活能力,改善生活质量,安全性较好。

objective： The efficacy of a combined therapy of low-dose of urokinase and nimodipine in the treatment of acute cerebral infarction has been observed. Methods： One hundred and twenty patients with acute cerebral infarction in 6- 72 hours after onset were randomly divided into the groups control, urokinase, and nimodipine. All the patients were given a basic therapy, and the patients in urokinase group were given the low-dose of urokinase, in nimodipine group the uroki nase along with nimodipine. The NIHSS and BI scales were used for evaluation before the treatment and at days 14 and 30 after the treatment. Results： At days 14 and 30 after the treatment, both the NIHSS and BI scores in the urokinase and nimodipine groups were statistically better than those in the control group （P〈0.05）. More importantly, the BI score in nimodipine group was significantly better than that in the urokinase group （P〈0. 05）. Conclusion： The combined therapy with low-dose of urokinase and nimodipine in the treatment of acute cerebral infarction may effectively and safely improve the outcome of patients with acute cerebral infarction.